Improving defences at the portal of HIV entry: mucosal and innate immunity.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Trichomoniasis and HIV interactions: a review.Sexually transmitted infections · 2013
   Pooled it
2. First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy.PloS one · 2011
   Trial
3. Metronidazole Treatment Failure and Persistent BV Lead to Increased Frequencies of Activated T- and Dendritic-Cell Subsets.Microorganisms · 2023
   Article
4. Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement-A new target for lupus treatment.Science advances · 2019
   Article
5. The Role of Defensins in HIV Pathogenesis.Mediators of inflammation · 2017
   Review
6. Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination.Vaccine · 2016
   Article
7. Recent Insights into the HIV/AIDS Pandemic.Microbial cell (Graz, Austria) · 2016
   Review
8. Effects of Female Sex Hormones on Susceptibility to HSV-2 in Vaginal Cells Grown in Air-Liquid Interface.Viruses · 2016
   Article
9. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques.PLoS pathogens · 2015
   Article
10. HIV vaccine research: the challenge and the way forward.Journal of immunology research · 2015
    Review
11. Aggregate complexes of HIV-1 induced by multimeric antibodies.Retrovirology · 2014
    Article
12. Organizing the HIV vaccine development effort.Current opinion in HIV and AIDS · 2013
    Review
13. Human cervicovaginal mucus contains an activity that hinders HIV-1 movement.Mucosal immunology · 2013
    Article
14. Isolation and characterization of intestinal epithelial cells from normal and SIV-infected rhesus macaques.PloS one · 2012
    Article
15. Inhibition of HIV-1 infection by human α-defensin-5, a natural antimicrobial peptide expressed in the genital and intestinal mucosae.PloS one · 2012
    Article
16. Retinoic acid as a vaccine adjuvant enhances CD8+ T cell response and mucosal protection from viral challenge.Journal of virology · 2011
    Article
17. A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells.Retrovirology · 2011
    Article
18. Stability and transport of cervical cytobrushes for isolation of mononuclear cells from the female genital tract.Journal of immunological methods · 2011
    Article
19. Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen.Vaccine · 2011
    Article
20. Blocking of α4β7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques.Journal of immunology (Baltimore, Md. : 1950) · 2011
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as